ICD E75.4ORPHA:216NCL

Batten Disease

Batten disease (neuronal ceroid lipofuscinosis) is a group of rare and fatal genetic neurological disorders that cause progressive deterioration of vision, seizures, and cognitive and motor decline, often beginning in childhood. The first approved enzyme replacement therapy (cerliponase alfa) targets CLN2 disease and has slowed progression.

559
Articles
47
Trials (5 AU)
Updated
26 March 2026
Loading...

Common Questions

What is Batten Disease?

Batten disease (neuronal ceroid lipofuscinosis) is a group of rare and fatal genetic neurological disorders that cause progressive deterioration of vision, seizures, and cognitive and motor decline, often beginning in childhood. The first approved enzyme replacement therapy (cerliponase alfa) targets CLN2 disease and has slowed progression.

How many clinical trials are available for Batten Disease?

RareWays currently indexes 47 clinical trials for Batten Disease, of which 10 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.

Where does the research data for Batten Disease come from?

RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.

Get research updates

Monthly email when new findings are published for Batten Disease.

No spam. Unsubscribe any time. Not medical advice.

This information is for general awareness only.

For guidance specific to your situation, please speak with your healthcare team.